

Literatura ACTA MEDICINAE

4/2022 Kazuistiky v onkologii, hematoonkologii a hematologii

- 2 **Pacientka s ALK+ nemalobuněčným karcinomem plic léčená lorlatinibem**
MUDr. Leona Koubková Pneumologická klinika 2. LF UK a FN v Motole, Praha
- 2 **Imunoterapie u pacientky s malobuněčným plicním karcinomem**
MUDr. Petra Zemanová Onkologická klinika VFN a 1. LF UK, Klinika TBC a respiračních nemocí 1. LF UK a VFN, Praha
doc. MUDr. Milada Zemanová, Ph.D. Onkologická klinika VFN a 1. LF UK, Praha
MUDr. Renata Jirásková Onkologická klinika VFN a 1. LF UK, Klinika TBC a respiračních nemocí 1. LF UK a VFN, Praha
prof. MUDr. Luboš Petruželka, CSc. Onkologická klinika VFN a 1. LF UK, Praha
- 2 **Pacientka s hepatocelulárním karcinomem a metastázami do plic: „Kolik lenvatinibu stačí?“**
MUDr. Marián Liberko | doc. MUDr. Renata Soumarová, Ph.D., MBA Radioterapeutická a onkologická klinika FNKV a 3. LF UK, Praha
- 2 **Farmakologický profil – Rozlytrek (entrectinib) – Lékový profil**
doc. MUDr. Jiří Slíva, Ph.D. Ústav farmakologie, 3. LF UK, Praha
- 2 **Dlouhodobá terapie pacientky s HER2 pozitivním karcinomem prsu**
MUDr. David Dufek | MUDr. Katarína Petráková, Ph.D. Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno
- 3 **Efekt neoadjuvantní duální HER2 blokady u pacientky s lokálně pokročilým HER2 pozitivním karcinomem prsu**
MUDr. Martina Zimovjanová, Ph.D. Onkologická klinika VFN a 1. LF UK, Praha
- 3 **Starší pacient s metastatickým kolorektálním karcinomem a mutací BRAF**
MUDr. Jiří Tomášek, Ph.D. Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno
- 3 **Imunoterapie kombinací ipilimumabu a nivolumabu a odložená nefrektomie u metastatického renálního karcinomu**
doc. MUDr. Tomáš Büchler, Ph.D. Onkologická klinika 1. LF UK a Fakultní Thomayerovy nemocnice, Praha
- 3 **Použitie antimykotika amfotericín B u komplikovaného covidového pacienta s multirezistentnou nákazou na UPV**
MUDr. Peter Kubiš, MBA Ústredná vojenská nemocnica SNP Ružomberok
- 4 **Karotidynie (TIPIK syndrom) u pacientky s paroxysmální noční hemoglobinurií**
prof. MUDr. Pavel Žák, Ph.D. | MUDr. Petra Bělohávková IV. interní hematologická klinika FN Hradec Králové a LF Hradec Králové
- 4 **Terapie azacytidinem v kombinaci s venetoklaxem – nový směr v léčbě akutní myeloidní leukemie**
doc. MUDr. Anna Jonášová Ph.D. I. interní klinika VFN a 1. LF UK, Praha
- 4 **Léčba akutní myeloidní leukemie indukčním režimem obsahujícím gemtuzumab ozogamicin (Mylotarg); kazuistické případy z ÚHK**
MUDr. Petr Soukup, MHA | MUDr. Jan Válka, Ph.D. Ústav hematologie a krevní transfuze, Praha
- 4 **Kaplicizumab v léčbě získané trombotické trombocytopenické purpury**
MUDr. Miriam Lánská, Ph.D. | doc. MUDr. Jakub Radocha, Ph.D. | MUDr. Benjamin Víšek | prof. MUDr. Pavel Žák, Ph.D. IV. interní hematologická klinika, FN a LF UK, Hradec Králové
- 5 **Koncentrát aktivovaných koagulačních faktorů (aPCC) v profylaxi u pacienta se získanou hemofilií – zkušenost ÚHK**
MUDr. Věra Geierová Ústav hematologie a krevní transfuze, Praha
- 5 **U pacienta s generalizovanou malignitou s aktivní onkologickou léčbou nebo vysokým rizikem recidivy tromboembolické nemoci je dobré zvážit antikoagulační udržovací léčbu delší než 6 měsíců**
prof. MUDr. Petra Tesařová, CSc. Onkologická klinika 1. LF UK a VFN, Praha
- 5 **Management anemie v předoperační péči – přehled léčby**
plk. gšt. MUDr. Miloš Bohoněk, Ph.D. Oddělení hematologie a krevní transfuze, Ústřední vojenská nemocnice – Vojenská fakultní nemocnice Praha
doc. MUDr. Jan Bláha, Ph.D., MHA Klinika anesteziologie, resuscitace a intenzivní medicíny, 1. lékařská fakulta Univerzity Karlovy a Všeobecná fakultní nemocnice v Praze

Pacientka s ALK+ nemalobuněčným karcinomem plic léčená lorlatinibem

MUDr. Leona Koubková Pneumologická klinika 2. LF UK a FN v Motole, Praha

- 1 Gainor, J. F. – Dardaei, L. – Yoda, S., et al.: Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. *Cancer Discov*, 2016, 6, s. 1118–1133.
- 2 Choi, Y. L. – Soda, M. – Yamashita, Y., et al.: ALK Lung Cancer Study Group: EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. *N Engl J Med*, 2010, 363, s. 1734–1739.
- 3 Sasaki, T. – Koivunen, J. – Ogino, A., et al.: A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. *Cancer Res*, 2011, 71, s. 6051–6060.
- 4 Solomon, B. J. – Besse, B. – Bauer, T. M., et al.: Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. *Lancet Oncol*, 2018, 19, s. 1654–1667.
- 5 Solomon, B. J. – Bauer, T. M. – De Marinis, F., et al.: Lorlatinib vs crizotinib in the first-line treatment of patients (pts) with advanced ALK-positive non-small-cell lung cancer (NSCLC): results of the phase III CROWN study. *Ann Oncol*, 2020, 31, suppl. 4, s. S1180–S1181.
- 6 SPC Lorviqua.

Imunoterapie u pacientky s malobuněčným plicním karcinomem

MUDr. Petra Zemanová Onkologická klinika VFN a 1. LF UK, Klinika TBC a respiračních nemocí 1. LF UK a VFN, Praha

doc. MUDr. Milada Zemanová, Ph.D. Onkologická klinika VFN a 1. LF UK, Praha

MUDr. Renata Jirásková Onkologická klinika VFN a 1. LF UK, Klinika TBC a respiračních nemocí 1. LF UK a VFN, Praha

prof. MUDr. Luboš Petruželka, CSc. Onkologická klinika VFN a 1. LF UK, Praha

- 1 de Groot, P. M. – Wu, C. C. – Carter, B. W., et al.: The epidemiology of lung cancer. *Transl Lung Cancer Res*, 2018, 7, s. 220–233.
- 2 Kalemkerian, G. P. – Gadgeel, S. M.: Modern staging of small cell lung cancer. *J Natl Compr Canc Netw*, 2013, 11, s. 99–104.
- 3 Slotman, B. – Faivre-Finn, C. – Kramer, G., et al.: EORTC Radiation Oncology Group and Lung Cancer Group: Prophylactic cranial irradiation in extensive small-cell lung cancer. *N Engl J Med*, 2007, 357, s. 664–672.
- 4 Neal, J. W. – Gubens, M. A. – Wakelee, H. A.: Current management of small cell lung cancer. *Clin Chest Med*, 2011, 32, s. 853–886.
- 5 Warde, P. – Payne, D.: Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. *J Clin Oncol*, 1992, 10, s. 890–895.
- 6 Slotman, B. J. – van Tinteren, H. – Praag, J. O. – et al.: Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. *Lancet*, 2015, 385, s. 36–42.
- 7 Aupérin, A. – Arriagada, R. – Pignon, J. P., et al.: Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. *N Engl J Med*, 1999, 341, s. 476–484.
- 8 Slotman, B. – Faivre-Finn, C. – Kramer, G., et al.: EORTC Radiation Oncology Group and Lung Cancer Group: Prophylactic cranial irradiation in extensive small-cell lung cancer. *N Engl J Med*, 2007, 357, s. 664–672.
- 9 Takahashi, T. – Yamanaka, T. – Seto, T., et al.: Prophylactic cranial irradiation versus observation in patients with extensive-diseases small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial. *Lancet Oncol*, 2017, 18, s. 663–671.
- 10 Neal, J. W. – Gubens, M. A. – Wakelee, H. A.: Current management of small cell lung cancer. *Clin Chest Med*, 2011, 32, s. 853–863.
- 11 George, J. – Lim, J. S. – Jang, S. J., et al.: Comprehensive genomic profiles of small cell lung cancer. *Nature*, 2015, 524, s. 47–53.
- 12 Mankor, J. M. – Paats, M. S. – Groenendijk, F. H., et al.: Impact of panel design and cut-off on tumour mutational burden assessment in metastatic solid tumour samples. *Br J Cancer*, 2020, 122, s. 953–956.
- 13 Paz-Ares, L. – Dvorkin, M. – Chen, Y., et al.: CASPIAN investigators: Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. *Lancet*, 2019, 394, s. 1929–1939.
- 14 Goldman, J. W. – Dvorkin, M. – Chen, Y., et al.: CASPIAN investigators: Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. *Lancet Oncol*, 2021, 22, s. 51–65.

Pacientka s hepatocelulárním karcinomem a metastázami do plic: „Kolik lenvatinibu stačí?“

MUDr. Marián Liberko | doc. MUDr. Renata Soumarová, Ph.D., MBA Radioterapeutická a onkologická klinika FNKV a 3. LF UK, Praha

- 1 Kudo, M. – Finn, R. S. – Qin, S., et al.: Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. *Lancet*, 2018, 391, s. 1163–1173.

Farmakologický profil – Rozlytrek (entrectinib) – Lékový profil

doc. MUDr. Jiří Slíva, Ph.D. Ústav farmakologie, 3. LF UK, Praha

- 1 Ardini, E. – Menichincheri, M. – Banfi, P.: Entrectinib, a pan-TRK, ROS1, and ALK inhibitor with activity in multiple molecularly defined cancer indications. *Mol Cancer Ther*, 2016, 15, s. 628–639.
- 2 Menichincheri, M. – Ardini, E. – Magnaghi, P., et al.: Discovery of entrectinib: a new 3-aminoindazole as a potent anaplastic lymphoma kinase (ALK), c-ros oncogene 1 kinase (ROS1), and pan-tropomyosin receptor kinases (Pan-TRKs) inhibitor. *J Med Chem*, 2016, 59, s. 3392–3408.
- 3 Drilon, A. – Li, G. – Dogan, S., et al.: What hides behind the MASCC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASCC). *Ann Oncol*, 2016, 27, s. 920–926.
- 4 Russo, M. – Misale, S. – Wei, G., et al.: Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer. *Cancer Discov*, 2016, 6, s. 36–44.
- 5 Chawla, N. – Bui, N. Q. – Seetharam, M.: Evolving role of entrectinib in treatment of NTRK-positive tumors. *Future Oncol*, 2021, 17, s. 2835–2846.
- 6 Meneses-Lorente, G. – Bentley, D. – Guerini, E., et al.: Characterization of the pharmacokinetics of entrectinib and its active M5 metabolite in healthy volunteers and patients with solid tumors. *Invest New Drugs*, 2021, 39, s. 803–811.
- 7 Frampton, J. E.: Entrectinib: a review in NTRK+ solid tumours and ROS1+ NSCLC. *Drugs*, 2021, 81, s. 697–708.
- 8 Dziadziuszko, R. – Krebs, M. G. – De Braud, F., et al.: Updated integrated analysis of the efficacy and safety of entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small-cell lung cancer. *J Clin Oncol*, 2021, 39, s. 1253–1263.
- 9 Drilon, A. – Siena, S. – Dziadziuszko, R., et al.: Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. *Lancet Oncol*, 2020, 21, s. 261–270.
- 10 Robinson, G. – Gajjar, A. – Gauvain, K., et al.: Phase I/IB trial to assess the activity of entrectinib in children and adolescents with recurrent or refractory solid tumors including central nervous system (CNS) tumors. *J Clin Oncol*, 2019, 37, suppl. 15, s. 10009.
- 11 SPC Rozlytrek, zdroj: www.sukl.cz.

Dlouhodobá terapie pacientky s HER2 pozitivním karcinomem prsu

MUDr. David Dufek | MUDr. Katarína Petránková, Ph.D. Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno

- 1 Hudis, C. A.: Trastuzumab — mechanism of action and use in clinical practice. *N Engl J Med*, 2007, 357.
- 2 Swain, S. M. – Baselga, J. – Kim, S. B., et al.: Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. *N Engl J Med*, 2015, 372, s. 724–734.
- 3 Verma, S. – Miles, D. – Gianni, L., et al.: Trastuzumab emtansine for HER2-positive advanced breast cancer. *N Engl J Med*, 2012, 367, s. 1783–1791.
- 4 Murthy, R. K. – Loi, S. – Okines, A., et al.: Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. *N Engl J Med*, 2020, 382, s. 597–609.
- 5 Beduk Esen, C. S. – Gultekin, M. – Yildiz, F.: Role of radiotherapy in oligometastatic breast cancer: Review of the literature. *World J Clin Oncol*, 2022, 13, s. 39–48.
- 6 Goss, P. E. – Smith, I. E. – O'Shaughnessy, J., et al.: Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial. *Lancet Oncol*, 2013, 14, s. 88–96.
- 7 Perez, E. A. – Barrios, C. – Eiermann, W., et al.: Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: final results from MARIANNE. *Cancer*, 2019, 125, s. 3974–3984.

Efekt neoadjuvantní duální HER2 blokády u pacientky s lokálně pokročilým HER2 pozitivním karcinomem prsu

MUDr. Martina Zimovjanová, Ph.D. Onkologická klinika VFN a 1. LF UK, Praha

- 1 von Minckwitz, G. – Huang, C. S. – Mano, M. S., et al.: Trastuzumab emtansine for residual invasive HER2-positive breast cancer. *N Engl J Med*, 2019, 380, s. 617–628.
- 2 Baselga, J. – Bradbury, I. – Eidtmann, H., et al.: NeoALLTO study team: Lapatinib with trastuzumab for HER2 positive early breast cancer (NeoALLTO): Randomised open label multicentre phase 3 trial. *Lancet*, 2012, 379, s. 633–640.
- 3 Fernandez-Martinez, A. – Krop, I. E. – Hillman, D. W., et al.: Survival, pathologic response, and genomics in CALGB 40601 (Alliance), a neoadjuvant phase III trial of paclitaxel-trastuzumab with or without lapatinib in HER2-positive breast cancer. *J Clin Oncol*, 2020, 38, s. 4184–4193.
- 4 Swain, S. M. – Tang, G. – Brauer, H. A., et al.: NSABP B-41, a randomized neoadjuvant trial: genes and signatures associated with pathologic complete response. *Clin Cancer Res*, 2020, 26, s. 4233–4241.
- 5 Schneeweiss, A. – Chia, S. – Hickish, T., et al.: Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline containing and anthracycline-free chemotherapy regimens in patients with HER2 positive early breast cancer: Randomised phase 2 cardiac safety study (TRYPHAENA). *Ann Oncol*, 2013, 2004, s. 2278–2284.
- 6 Gianni, L. – Pienkowski, T. – Im, Y. H., et al.: Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced inflammatory or early HER2 positive breast cancer (NeoSphere): Randomised multicentre open label phase II trial. *Lancet Oncol*, 2012, 13, s. 25–32.
- 7 Gianni, L. – Eiermann, W. – Semiglazov, V., et al.: Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. *Lancet*, 2010, 375, s. 377–384.
- 8 Ismael, G. – Hegg, R. – Muehlbauer, S., et al.: Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. *Lancet Oncol*, 2012, 13, s. 869–878.
- 9 Shao, Z. – Pang, D. – Yang, H., et al.: Efficacy, safety, and tolerability of pertuzumab, trastuzumab, and docetaxel for patients with early or locally advanced ERBB2-positive breast cancer in Asia. The PEONY phase 3 randomized clinical trial. *Jama Oncol*, 2020, 6, s. e193692.
- 10 Hurvitz, S. A. – Martin, M. – Symmans, W. F., et al.: Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. *Lancet*, 2018, 19, s. 115–126.
- 11 Swain, S. M. – Ever, M. S. – Viale, G., et al.: Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study. *Ann Oncol*, 2018, 29, s. 646–653.
- 12 Schneeweiss, A. – Moebus, V. – Tesch, H., et al.: A randomised phase III trial comparing two dose-dense, dose-intensified approaches (EPC and PM(Cb)) for neoadjuvant treatment of patients with high-risk early breast cancer (GeparOcto). *J Clin Oncol*, 2017, 35, suppl. 15, s. 518–518.
- 13 Loibl, S. – Jackisch, C. – Schneeweiss, A., et al.: Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial. *Ann Oncol*, 2017, 28, s. 797–804.
- 14 Van Ramshorst, M. S. – van der Voort, A. – van Werkhoven, E. D., et al.: Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial. *Lancet Oncol*, 2018, 19, s. 1360–1640.

Starší pacient s metastatickým kolorektálním karcinomem a mutací BRAF

MUDr. Jiří Tomášek, Ph.D. Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno

- 1 Kopetz, S. – Grothey, A. – Yaeger, R., et al.: Encorafenib, binimetinib, and cetuximab in BRAF V600E – mutated colorectal cancer. *N Engl J Med*, 2019, 381, s. 1632–1643.
- 2 *Modrá kniha České onkologické společnosti*. 2022, dostupné online z www.links.cz.
- 3 Tabernero, J. – Grothey, A. – Van Cutsem, E., et al.: Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON study. *J Clin Oncol*, 2021, 39, s. 273–284.
- 4 SPC ERBITUX (cetuximab).
- 5 SPC BRAFTOVI (encorafenib).

Imunoterapie kombinací ipilimumabu a nivolumabu a odložená nefrektomie u metastatického renálního karcinomu

doc. MUDr. Tomáš Büchler, Ph.D. Onkologická klinika 1. LF UK a Fakultní Thomayerovy nemocnice, Praha

- 1 Motzer, R. J. – Tannir, N. M. – McDermott, D. F., et al.: Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. *N Engl J Med*, 2018, 378, s. 1277–1290.
- 2 Motzer, R. J. – Tannir, N. M. – McDermott, D. F., et al.: 661P – Conditional survival and 5-year follow-up in CheckMate 214: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in advanced renal cell carcinoma (aRCC). *Annals of Oncology*, 2021, 32, suppl. 5, s. S678–S724.
- 3 Mejean, A. – Ravaud, A. – Thezenas, S., et al.: Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. *N Engl J Med*, 2018, 379, s. 417–427.
- 4 Poprach, A. – Holanek, M. – Chloupkova, R., et al.: Cytoreductive nephrectomy and overall survival of patients with metastatic renal cell carcinoma treated with targeted therapy – data from the national renal registry. *Cancers*, 2020, 12, s. 2911.
- 5 Singla, N. – Hutchinson, R. C. – Ghandour, R. A., et al.: Improved survival after cytoreductive nephrectomy for metastatic renal cell carcinoma in the contemporary immunotherapy era: An analysis of the National Cancer Database. *Urol Oncol*, 2020, 38, s. 604.e9–604.e17.
- 6 Woldu, S. L. – Brugarolas, J. – Kapur, P., et al.: What is the role of nephrectomy following complete response to checkpoint inhibitors? *Urol Case Rep*, 2018, 18, s. 60–63.
- 7 Pignot, G. – Thiery-Vuillemin, A. – Walz, J., et al.: Nephrectomy after complete response to immune checkpoint inhibitors for metastatic renal cell carcinoma: A new surgical challenge? *Eur Urol*, 2020, 77, s. 761–763.
- 8 Gao, J. – Karam, J. A. – Tannir, N. M., et al.: A pilot randomized study evaluating nivolumab (nivo) or nivo + bevacizumab (bev) or nivo + ipilimumab (ipi) in patients with metastatic renal cell carcinoma (MRCC) eligible for cytoreductive nephrectomy, metastasectomy or post-treatment biopsy (Bx). *J Clin Oncol*, 2019, 37, suppl. s. 4501–4501.

Použití antimykotika amfotericín B u komplikovaného covidového pacienta s multirezistentnou nákazou na UPV

MUDr. Peter Kubiš, MBA Ústřední vojenská nemocnice SNP Ružomberok

- 1 Gallagher, J. C. – Dodds Ashley, E. S. – Drew, R. H., et al.: Antifungal pharmacotherapy for invasive mould infections. *Expert Opin Pharmacother*, 2003, 4, s. 147–164.
- 2 Ullmann, A. J. – Aguado, J. M. – Arikan-Akdagli, S., et al.: Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. *Clin Microbiol Infect*, 2018, 24, suppl. 1, s. e1–e38.
- 3 Mistro, S. – de M Maciel, I. – de Menezes, R. G., et al.: Does lipid emulsion reduce amphotericin B nephrotoxicity? A systematic review and meta-analysis. *Clin Infect Dis*, 2012, 54, s. 1774.
- 4 Tissot, F. – Agrawal, S. – Pagano, L., et al.: GUIDELINES. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. *Haematologica*, 2017, 102, dostupné z: <https://doi.org/10.3324/haematol.2016.152900>, vyhledáno 22. 4. 2022.
- 5 Ráčil, Z. – Haber, J. – Drgoňa, L., et al.: Empirická antimykotická léčba febrilní neutropenie u nemocných s hematologickou malignitou – doporučení odborníků – s podporou CELL, CHS JEP, COS JEP, SOS. *Postgrad Med*, 2010, suppl., s. 23–25.
- 6 Imhof, A. – Balajee, S. A. – Fredricks, D. N., et al.: Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. *Clin Infect Dis*, 2004, 39, s. 743.
- 7 Drgoňa, L.: Diagnostika a liečba invazívnych mykóz u hematologických pacientov. *Onkologie*, 2009, 3, s. 231–234.
- 8 Maschmeyer, G.: The changing epidemiology of invasive fungal infections: new threats. *Int J Antimicrob Agents*, 2006, 27, s. 53–6.
- 9 Patterson, T. F. – Thompson, G. R. 3rd. – Denning, D. W., et al.: Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. *Clin Infect Dis*, 2016, 63, s. e1.
- 10 Marr, K. A. – Schlamm, H. T. – Herbrecht, R., et al.: Combination antifungal therapy for invasive aspergillosis: a randomized trial. *Ann Intern Med*, 2015, 162, s. 81.

Karotidyne (TIPIC syndrom) u pacientky s paroxysmální noční hemoglobinurií

prof. MUDr. Pavel Žák, Ph.D. | MUDr. Petra Bělohávková IV. interní hematologická klinika FN Hradec Králové a LF Hradec Králové

- 1 Fay, T.: Atypical facial neuralgia. *Arch Neurol Psychiatr*, 1927, 18, s. 309–315.
- 2 Krótká, I. – Eliáš, P. – Jandura, J.: Využití CT a UZ v zobrazovací diagnostice TIPIC syndromu (karotidyne). *Ces Radiol*, 2020, 74, s. 222–225.
- 3 Lecler, A. – Obadia, M. – Savatovsky, J., et al.: TIPIC syndrome: beyond the myth of carotidyne. A new distinct unclassified entity. *AJNR Am J Neuroradiol*, 2017, 38, s. 1391–1398.

Terapie azacitidinem v kombinaci s venetoklaxem – nový směr v léčbě akutní myeloidní leukemie

doc. MUDr. Anna Jonášová Ph.D. I. interní klinika VFN a 1. LF UK, Praha

- 1 Song, X. – Peng, Y. – Wang, X., et al.: Incidence, survival, and risk factors for adults with acute myeloid leukemia not otherwise specified and acute myeloid leukemia with recurrent genetic abnormalities: analysis of the Surveillance, Epidemiology, and End Results (SEER) database, 2001–2013. *Acta Haematol*, 2018, 139, s. 115–127.
- 2 Döhner, H. – Estey, E. – Grimwade, D., et al.: Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. *Blood*, 2017, 129, s. 424–447.
- 3 Dombret, H. – Seymour, J. F. – Butrym, A., et al.: International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. *Blood*, 2015, 126, s. 291–299.
- 4 DiNardo, C. D. – Pratz, K. – Pullarkat, V., et al.: Venetoclax combined with decitabine or azacitidine in treatment-naïve, elderly patients with acute myeloid leukemia. *Blood*, 2019, 133, s. 7–17.
- 5 Fenaux, P. – Mufti, G. J. – Hellstrom-Lindberg, E., et al.: International Vidaza High-Risk MDS Survival Study Group: Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. *Lancet Oncol*, 2009, 10, s. 223–232.
- 6 Adams, C. M. – Clark-Garvey, S. – Porcu, P., et al.: Targeting the Bcl-2 family in B cell lymphoma. *Front Oncol*, 2019, 8, s. 636–636.
- 7 Pan, R. – Hogdal, L. J. – Benito, J. M., et al.: Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. *Cancer Discov*, 2014, 4, s. 362–375.
- 8 Lagadinou, E. D. – Sach, A. – Callahan, K., et al.: BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. *Cell Stem Cell*, 2013, 12, s. 329–341.
- 9 Konopleva, M. – Contractor, R. – Tsao, T., et al.: Mechanisms of apoptosis sensitivity and resistance to the BHL3 mimetic ABT-737 in acute myeloid leukemia. *Cancer Cell*, 2006, 10, s. 375–388.
- 10 Campos, L. – Rouault, J. P. – Sabido, O., et al.: High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. *Blood*, 1993, 81, s. 3091–3096.
- 11 Mehta, S. V. – Shukla, S. N. – Vora, H. H.: Overexpression of Bcl2 protein predicts chemoresistance in acute myeloid leukemia: its correlation with FLT3. *Neoplasma*, 2013, 60, s. 666–675.
- 12 Karakas, T. – Miething, C. C. – Maurer, U., et al.: The coexpression of the apoptosis-related genes bcl-2 and wt1 in predicting survival in adult acute myeloid leukemia. *Leukemia*, 2002, 16, s. 846–854.
- 13 Konopleva, M. – Polley, D. A. – Potluri, J., et al.: Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. *Cancer Discov*, 2016, 6, s. 1106–1117.
- 14 Jin, S. – Cojocari, D. – Purkal, J. J., et al.: 5-Azacitidine induces NOXA to prime AML cells for venetoclax-mediated apoptosis. *Clin Cancer Res*, 2020, 26, s. 3371–3383.
- 15 Bogenberger, J. M. – Delman, D. – Hansen, N., et al.: Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies. *Leuk Lymphoma*, 2015, 56, s. 226–229.
- 16 DiNardo, C. D. – Pratz, K. W. – Letai, A., et al.: Safety and preliminary efficacy of venetoclax with decitabine (Dec) or azacitidine (Aza) in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. *Lancet Oncol*, 2018, 19, s. 216–228.
- 17 Polley, D. A. – Pratz, K. W. – Jonas, B. A., et al.: Venetoclax in combination with hypomethylating agents induces rapid, deep, and durable responses in patients with AML ineligible for intensive therapy. *Blood*, 2018, 132, suppl. 1, s. 285, dostupné z: <https://doi.org/10.1182/blood-2018-99-117179>, vyhledáno 13. 4. 2022.
- 18 DiNardo, C. D. – Jonas, B. A. – Pullarkat, V., et al.: Azacitidine and venetoclax in previously untreated acute myeloid leukemia. *N Engl J Med*, 2020, 383, s. 617–629.
- 19 Cherry, I. M. – Abbott, D. – Amaya, M., et al.: Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia. *Blood*, 2021, 5, s. 5565–5573.
- 20 Reville, P. K. – Kantarjian, H. – Borthakur, G., et al.: Phase II study of venetoclax added to cladribine (CLAD) and low dose AraC (LDAC) alternating with 5-azacytidine (AZA) in older and unfit patients with newly diagnosed acute myeloid leukemia (AML). *Blood*, 138, suppl. 1, s. 367–367.
- 21 Kadia, T. M. – Reville, P. K. – Borthakur, G., et al.: Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial. *Lancet Haematol*, 2021, 8, s. e552–e561.

Léčba akutní myeloidní leukemie indukčním režimem obsahujícím gemtuzumab ozogamicin (Mylotarg); kazuistické případy z ÚHK

MUDr. Petr Soukup, MHA | MUDr. Jan Válka, Ph.D. Ústav hematologie a krevní transfuze, Praha

- 1 Lambert, J. – Pautas, C. – Terré, C., et al.: Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial. *Haematologica*, 2019, 104, s. 113–119.
- 2 Ricart, A. D.: Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin. *Clin Cancer Res*, 2011, 17, s. 6417–6427.
- 3 Souhrn údajů o přípravku MYLOTARG. Brusel, Belgie: Pfizer; 2020.
- 4 Olombel, G. – Guerin, E. – Guy, J., et al.: The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia. *Blood*, 2016, 127, s. 2157–2160.
- 5 De Propriis, M. S. – Raponi, S. – Diverio, D., et al.: High CD33 expression levels in acute myeloid leukemia cells carrying the nucleophosmin (NPM1) mutation. *Haematologica*, 2011, 96, s. 1548–1551.
- 6 SÚKL, Mylotarg, Ceny a úhrady, dostupné z: <https://www.sukl.cz/modules/medication/detail.php?code=0222910&tab=prices>, vyhledáno 13. 4. 2022.
- 7 SPC Mylotarg, SÚKL, dostupné z: <https://www.sukl.cz/modules/medication/detail.php?code=0222910&tab=texts>, vyhledáno 13. 4. 2022.

Kaplicizumab v léčbě získané trombotické trombocytopenické purpury

MUDr. Miriam Lánská, Ph.D. | doc. MUDr. Jakub Radocha, Ph.D. | MUDr. Benjamin Víšek | prof. MUDr. Pavel Žák, Ph.D.

IV. interní hematologická klinika, FN a LF UK, Hradec Králové

- 1 Scully, M. – Cataland, S. – Coppo, P., et al.: Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. *J Thromb Haemost*, 2017, 15, s. 312–322.
- 2 Subhan, M. – Scully, M.: Advances in the management of TTP. *Blood Rev*, 2022, doi: 10.1016/j.blre.2022.100945, online před tiskem.
- 3 Sukumar, S. – Lämmle, B. – Cataland, S. R.: Thrombotic thrombocytopenic purpura: Pathophysiology, diagnosis, and management. *J Clin Med*, 2021, 10, s. 536.
- 4 Bendapudi, P. K., et al.: Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study. *Lancet Haematol*, 2017, 4, s. e157–e164.
- 5 Domingo-González, A., et al.: Application of the French TMA Reference Center Score and the mortality in TTP Score in de novo and relapsed episodes of acquired thrombotic thrombocytopenic purpura at a tertiary care facility in Spain. *J Clin Apher*, 2021, 36, s. 420–428.
- 6 Scully, M. – Regalado-Artamendi, I. – Martín-Rojas, R. M., et al.: Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. *Engl J Med*, 2019, 380, s. 335–346.
- 7 Moschkowitz, E.: Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease. *Proc NY Pathol Soc*, 1924, 24, s. 21–24.
- 8 Rock, G. A. – Shumak, K. H. – Buskard, N. A., et al.: Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. *N Engl J Med*, 1991, 325, s. 393–397.
- 9 Padmanabhan, A. – Connelly-Smith, L. – Aquil, N., et al.: Guidelines on the use of therapeutic plasma exchange in clinical practice—evidence-based approach from the Writing Committee of the American Society for Apheresis: the eighth special issue. *J Clin Apher*, 2019, 34, s. 71–354.
- 10 Cataland, S. R., et al.: Cyclosporine or steroids as an adjunct to plasma exchange in the treatment of immune-mediated thrombotic thrombocytopenic purpura. *Blood Adv*, 2017, 1, s. 2075–2082.
- 11 Zheng, X. L. – Vesely, S. K. – Cataland, S. R., et al.: ISTH guidelines for treatment of thrombotic thrombocytopenic purpura. *J Thromb Haemost*, 2020, 18, s. 2496–2502.
- 12 Scully, M., et al.: A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. *Blood*, 2011, 118, s. 1746–1753.
- 13 Page, E. E. – Kremer Hovink, J. A. – Terrell, D. R., et al.: Rituximab reduces risk for relapse in patients with thrombotic thrombocytopenic purpura. *Blood*, 2016, 127, s. 3092–3094.
- 14 Völker, L. A. – Kaufeld, J. – Meisbach, W., et al.: Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura. *Blood Adv*, 2020, 4, s. 3085–3092.
- 15 Logothetis, C. N. – Patel, P. – Eatrisedet, J., et al.: Post approval experience with caplacizumab for acquired thrombotic thrombocytopenic purpura at a single institution. *J Clin Med*, 2021, 10, s. 3418.
- 16 Coppo, P. – Bubenheim, M. – Azoulay, E., et al.: A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP. *Blood*, 2021, 137, s. 733–742.

Koncentrát aktivovaných koagulačních faktorů (aPCC) v profylaxi u pacienta se získanou hemofilií – zkušenost ÚHKT

MUDr. Věra Geierová Ústav hematologie a krevní transfuze, Praha

- Collins, P, et al.: Diagnosis and management of acquired coagulation inhibitors: a guideline from UKHCDO. *BJH*, 2013, 162, s. 758–773.
- Baudo, F, et al.: Management of bleeding in acquired hemophilia A: results from the European Acquired Hemophilia (EACH2) Registry. *Blood*, 2012, 120, s. 39–46.
- Tiede, A. – Collins, P. – Knoebel, P., et al.: GUIDELINES. International recommendations on the diagnosis and treatment of acquired hemophilia A. *Haematologica*, 2020, 105, s. 1791–1801.
- Tiede, A. – Klamroth, R. – Schaft, R. E., et al.: Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study. *Blood*, 2015, 125, s. 1091–1097.

U pacienta s generalizovanou malignitou s aktivní onkologickou léčbou nebo vysokým rizikem recidivy tromboembolické nemoci je dobré zvážit antikoagulační udržovací léčbu delší než 6 měsíců

prof. MUDr. Petra Tesařová, CSc. Onkologická klinika 1. LF UK a VFN, Praha

- Khorana, A. A. – Mackman, N. – Falanga, A., et al.: Cancer-associated venous thromboembolism. *Nat Rev Dis Primers*, 2022, 8, s. 112.
- Lyman, G. H. – Culakova, E. – Poniewierski, M. S., et al.: Morbidity, mortality and costs associated with venous thromboembolism in hospitalized patients with cancer. *Thromb Res*, 2018, 164, suppl. 1, s. S112–S118.
- Lyman, G. H. – Carrier, M. – Ay, C., et al.: American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. *Blood Adv*, 2021, 5, s. 927–974.
- Kahale, L. A. – Matar, C. F. – Hakoum, M. B., et al.: Anticoagulation for the initial treatment of venous thromboembolism in people with cancer. *Cochrane Database Syst Rev*, 2018, 2018, s. CD006649.
- Rossel, A. – Robert-Ebadi, H. – Combescur, C., et al.: Anticoagulant therapy for acute venous thrombo-embolism in cancer patients: A systematic review and network meta-analysis. *PLoS One*, 2019, 14, s. e0213940.
- Riaz, I. B. – Fuentes, H. E. – Naqvi, S. A. A., et al.: Direct oral anticoagulants compared with dalteparin for treatment of cancer-associated thrombosis: a living, interactive systematic review and network meta-analysis. *Mayo Clin Proc*, 2022, 97, s. 308–324.
- Mulder, F. I. – Horváth-Puhó, E. – Vas Es, N., et al.: Venous thromboembolism in cancer patients: a population-based cohort study. *Blood*, 2021, 137, s. 1959–1969.
- Moik, F. – Ay, C. – Pabinger, I.: Risk prediction for cancer-associated thrombosis in ambulatory patients with cancer: past, present and future. *Thromb Res*, 2020, 191, suppl. 1, s. S3–S11.
- Abdulla, A. – Davic, W. M. – Ratnaweera, N., et al.: A meta-analysis of case fatality rates of recurrent venous thromboembolism and major bleeding in patients with cancer. *Thromb Haemost*, 2020, 120, s. 702–713.
- Prandoni, P. – Lensing, A. W. A. – Piccoli, A., et al.: Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. *Blood*, 2002, 100, s. 3484–3488.
- Eichinger, S.: Cancer associated thrombosis: risk factors and outcomes. *Thromb Res*, 2016, 140, suppl. 1, s. S12–S17.
- Mulder, F. I. – Di Nisio, M. – Ay, C., et al.: Clinical implications of incidental venous thromboembolism in cancer patients. *Eur Respir J*, 2020, 55, s. 1901697.
- Trujillo-Santos, J. – Nieto, J. A. – Tiberio, G., et al.: Predicting recurrences or major bleeding in cancer patients with venous thromboembolism. *Thromb Haemost*, 2008, 100, s. 435–439.

Management anemie v předoperační péči – přehled léčby

plk. gšt. MUDr. Miloš Bohoněk, Ph.D. Oddělení hematologie a krevní transfuze, Ústřední vojenská nemocnice – Vojenská fakultní nemocnice Praha

doc. MUDr. Jan Bláha, Ph.D., MHA Klinika anesteziologie, resuscitace a intenzivní medicíny, 1. lékařská fakulta Univerzity Karlovy a Všeobecná fakultní nemocnice v Praze

- Global Forum for Blood Safety: Patient Blood Management. WHO, 14.–15. 3. 2011, Dubaj, Spojené arabské emiráty. Dostupné z: https://cdn.who.int/media/docs/default-source/biologicals/blood-products/document-migration/gfbs_01_pbm_concept_paper.pdf?sfvrsn=f189661_3, vyhledáno 20. 4. 2022.
- Vymazal, T. – Kocian, P. – Píkrýl, P., et al.: ERAS v české nemocnici – utopie, nebo realita? *Anest Intenziv Med*, 2018, 29, s. 317–321.
- Nørgaard, A., Kurz, J., Zacharowski, K., et al.: European Commission, Consumers, Health, Agriculture and Food Executive Agency: Building national programmes on Patient Blood Management (PBM) in the EU: a guide for health authorities. Publications Office, 2017, dostupné z: <https://data.europa.eu/doi/10.2818/54568>, vyhledáno 20. 4. 2022.
- Farmer, S. L. – Towler, S. C. – Leahy, M. F., et al.: Drivers for change: Western Australia Patient Blood Management Program (WA PBMP), World Health Assembly (WHA) and Advisory Committee on Blood Safety and Availability (ACBSA). *Best Pract Res Clin Anaesthesiol*, 2013, 27, s. 43–58.
- Meybohm, P. – Herrmann, E. – Steinbicker, A. U., et al.: Patient blood management is associated with a substantial reduction of red blood cell utilization and safe for patient's outcome: A prospective, multicenter cohort study with a noninferiority design. *Ann Surg*, 2016, 264, s. 203–211.
- Zacharowski, K. – Spahn, D. R.: Patient blood management equals patient safety. *Best Pract Res Clin Anaesthesiol*, 2016, 30, s. 159–169.
- Slipac, J.: European guide on good practices for Patient Blood Management. *Prakt Léč*, 2017, 97, s. 206–213.
- Althoff, F. C. – Neb, H. – Herrmann, E., et al.: Multimodal patient blood management program based on a three-pillar strategy. *Ann Surg*, 2019, 269, s. 794–804.
- WHO. Dostupné z: https://www.who.int/health-topics/anaemia#tab=tab_1, vyhledáno 20. 4. 2022.
- Čermák, J.: Léčba anemie a nedostatku železa z pohledu hematologa. *Kardiol Rev Int Med*, 2014, 16, s. 359–363.
- Ko, C. Y. – Hall, B. L. – Hart, A. J., et al.: The American College of Surgeons National Surgical Quality Improvement Program: achieving better and safer surgery. *Jt Comm J Qual Patient Saf*, 2015, 41, s. 199–204.
- Beguin, Y.: Soluble transferrin receptor for the evaluation of erythropoiesis and iron status. *Clin Chim Acta*, 2003, 329, s. 9–22.
- Muñoz, M. – Acheson, A. G. – Auerbach, M., et al.: International consensus statement on the peri-operative management of anaemia and iron deficiency. *Anaesthesia*, 2017, 72, s. 233–247.
- World Health Organization, 2011. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. World Health Organization. Dostupné z: <https://apps.who.int/iris/handle/10665/85839>, vyhledáno 20. 4. 2022.
- Simon, G. I. – Craswell, A. – Thom, O., et al.: Impacts of aging on anemia tolerance, transfusion thresholds, and patient blood management. *Transf Med Rev*, 2019, 33, s. 154–161.
- Musallam, K. M. – Tamim, H. M. – Richards, T., et al.: Preoperative anaemia and postoperative outcomes in non-cardiac surgery: a retrospective cohort study. *Lancet*, 2011, 378, s. 1396–407.
- Trentino, K. M., et al.: Screening and treating pre-operative anaemia and suboptimal iron stores in elective colorectal surgery: a cost-effectiveness analysis. *Anaesthesia*, 2021, 76, s. 357–365.
- Martin-Malo, A. – Borchard, G. – Flühmann, B., et al.: Differences between intravenous iron products: focus on treatment of iron deficiency in chronic art failure patients. *ESC Heart Fail*, 2019, 6, s. 241–253.
- Kei, T. – Mistry, N. – Curley, G., et al.: Efficacy and safety of erythropoietin and iron therapy to reduce red blood cell transfusion in surgical patients: a systematic review and meta-analysis. *Can J Anesth*, 2019, 66, s. 716–731.
- Cho, B. C. – Serini, J. – Zorrilla-Vaca, A., et al.: Impact of preoperative erythropoietin on allogeneic blood transfusions in surgical patients: results from a systematic review and meta-analysis. *Anesth Analg*, 2019, 128, s. 981–992.